Lung disorder

Summary

Lung disorder (MONDO:0005275) is a disease (an umbrella term covering 33 Mondo subtypes) with 2 cohort genes (8 GWAS associations across 29 studies) and 865 clinical trials. Top therapeutic interventions include dexmedetomidine, pemetrexed, and theophylline anhydrous.

At a glance

• Umbrella term: 33 Mondo subtypes
• Cohort genes: 2
• GWAS associations: 8
• ClinVar variants: 2
• Clinical trials: 865

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lung disorder
Mondo ID	MONDO:0005275
EFO	EFO:0003818
MeSH	D008171
DOID	DOID:850
NCIT	C3198
SNOMED CT	19829001
UMLS	C0024115
MedGen	7399
Anatomy (UBERON)	UBERON:0002048
Is cancer (heuristic)	no

Also known as: disease of lung · disease or disorder of lung · disorder of lung · lung disease · lung disease or disorder · lung disorder · lung disorders · pulmonary disease · pulmonary diseases · pulmonary disorder · pulmonary disorders

Data availability: 2 ClinVar variants · 8 GWAS associations (29 studies).

Disease family

An umbrella term covering 33 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder

Related subtypes (4): bronchial disorder, pleural disorder, tracheal disorder, tracheobronchitis

Subtypes (33): aspiration pneumonia, lung abscess, pneumonic plague, pulmonary alveolar proteinosis, pulmonary systemic sclerosis, obstructive lung disease, bronchiolitis, pulmonary immaturity, rheumatoid arthritis-associated interstitial lung disease, pulmonary embolism and infarction, acute chest syndrome, fungal lung infectious disease, middle lobe syndrome, pulmonary coin lesion, pulmonary plasma cell granuloma, silo filler disease, pulmonary alveolar microlithiasis, pulmonary venoocclusive disease, acute lung injury, interstitial lung disease, hantavirus pulmonary syndrome, pulmonary non-tuberculous mycobacterial infection, respiratory failure, lung neoplasm, occupational lung disease, Wilson-Mikity syndrome, neonatal aspiration syndrome, pneumonitis, vanishing lung syndrome, restrictive pulmonary disease, shrinking lung syndrome, dystrophic pulmonary ossification, pulmonary artery disease

Genetics & variants

GWAS landscape

8 GWAS associations across 29 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr15:78896129	8e-16		A	0.1
rs55781567	2e-15	CHRNA5	C	0.1
rs113993960	1e-14	CFTR	?	1.76
rs8040868	3e-12	CHRNA3	T	0.07
rs2036527	4e-12	PSMA4 - CHRNA5	G	0.07
rs138690638	3e-11	LINC02856 - KRT18P8	C	2.64
rs571627134	4e-11	NCR2 - FOXP4-AS1	C	2.47
rs186299082	3e-08	C17orf58 - KPNA2	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90476917	Verma A	2024	20,971	294,697	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476038	Verma A	2024	20,588	406,811	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90080159	Backman JD	2021	20,378	357,232	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084145	Backman JD	2021	20,378	357,232	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90476374	Verma A	2024	15,292	300,376	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476876	Verma A	2024	8,738	306,930	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477001	Verma A	2024	7,112	308,556	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473716	UK Biobank Whole-Genome Sequencing Consortium	2025	5,276	453,164	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90478178	Verma A	2024	4,346	111,988	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480267	Verma A	2024	4,346	111,988	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	1
Tier 3: regulatory	1
Tier 4: intronic/intergenic	5

MAF distribution

Bucket	Variants
common (>=0.05)	6
low_freq (0.01-0.05)	0
rare (<0.01)	2
unknown	0

Functional consequences

Consequence	Count
intergenic_variant	3
unknown	1
5_prime_UTR_variant	1
inframe_insertion	1
synonymous_variant	1
regulatory_region_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr15:78896129				0.341			8e-16	Tier 4: intronic/intergenic
rs55781567	15	78565644	C>G	0.32	5_prime_UTR_variant	CHRNA5	2e-15	Tier 2: splice/UTR
rs113993960	7	117559591	ATCT>A,ATCTTCT	0.05	inframe_insertion	CFTR	1e-14	Tier 1: coding
rs8040868	15	78618839	T>A,C	0.395	synonymous_variant	CHRNA3	3e-12	Tier 4: intronic/intergenic
rs2036527	15	78559273	G>A,C,T	0.301	intergenic_variant	PSMA4 - CHRNA5	4e-12	Tier 4: intronic/intergenic
rs138690638	18	9650854	C>T	0.001	intergenic_variant	LINC02856 - KRT18P8	3e-11	Tier 4: intronic/intergenic
rs571627134	6	41435303	C>T	0.001	intergenic_variant	NCR2 - FOXP4-AS1	4e-11	Tier 4: intronic/intergenic
rs186299082	17	68019976	G>A,C	0.05	regulatory_region_variant	C17orf58 - KPNA2	3e-08	Tier 3: regulatory

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 uncertain significance, 1 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
884386	NM_001089.3(ABCA3):c.3613G>A (p.Gly1205Arg)	ABCA3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2957958	NM_022042.4(SLC26A1):c.139C>T (p.Arg47Trp)	IDUA	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 7 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ABCA3	Orphanet:2032	Idiopathic pulmonary fibrosis
ABCA3	Orphanet:217563	Neonatal acute respiratory distress syndrome
ABCA3	Orphanet:440402	Interstitial lung disease due to ABCA3 deficiency
ABCA3	Orphanet:685082	Pediatric acute respiratory distress syndrome
IDUA	Orphanet:93473	Hurler syndrome
IDUA	Orphanet:93474	Scheie syndrome
IDUA	Orphanet:93476	Hurler-Scheie syndrome

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ABCA3	HGNC:33	ENSG00000167972	Q99758	Phospholipid-transporting ATPase ABCA3	clinvar
IDUA	HGNC:5391	ENSG00000127415	P35475	Alpha-L-iduronidase	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ABCA3	Phospholipid-transporting ATPase ABCA3	Catalyzes the ATP-dependent transport of phospholipids such as phosphatidylcholine and phosphoglycerol from the cytoplasm into the lumen side of lamellar bodies, in turn participates in the lamellar bodies biogenesis and homeostasis of pul…

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transporter	1	38.9×	0.051
Antibody/Immunoglobulin	1	14.6×	0.067

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ABCA3	Transporter	yes		ABC_transporter-like_ATP-bd, AAA+_ATPase, ABC2_TM
IDUA	Antibody/Immunoglobulin	yes	3.2.1.76	Glyco_hydro_39, Ig-like_fold, GH_hydrolase_sf

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
lower lobe of lung	1
upper lobe of left lung	1
upper lobe of lung	1
cerebellar cortex	1
cerebellar hemisphere	1
right hemisphere of cerebellum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ABCA3	222	ubiquitous	marker	lower lobe of lung, upper lobe of lung, upper lobe of left lung
IDUA	209	ubiquitous	marker	right hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
IDUA	1,927
ABCA3	1,436

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
IDUA	P35475	11
ABCA3	Q99758	2

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 16. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
MPS I - Hurler syndrome (HS-GAG degradation)	1	5710.0×	7e-04	IDUA
Defective ABCA3 causes SMDP3	1	5710.0×	7e-04	ABCA3
MPS I - Hurler syndrome (CS/DS degradation)	1	5710.0×	7e-04	IDUA
Diseases associated with surfactant metabolism	1	1427.5×	0.002	ABCA3
ABC transporters in lipid homeostasis	1	300.5×	0.008	ABCA3
CS/DS degradation	1	271.9×	0.008	IDUA
HS-GAG degradation	1	248.3×	0.008	IDUA
ABC transporter disorders	1	219.6×	0.008	ABCA3
Surfactant metabolism	1	184.2×	0.009	ABCA3
Disorders of transmembrane transporters	1	69.6×	0.021	ABCA3
ABC-family protein mediated transport	1	60.7×	0.022	ABCA3
Diseases of metabolism	1	40.2×	0.030	ABCA3
Transport of small molecules	1	12.6×	0.089	ABCA3
Disease	1	6.5×	0.155	ABCA3
Metabolism of proteins	1	6.2×	0.155	ABCA3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
disaccharide metabolic process	1	8426.0×	9e-04	IDUA
heparin proteoglycan catabolic process	1	8426.0×	9e-04	IDUA
positive regulation of protein homooligomerization	1	8426.0×	9e-04	ABCA3
regulation of phosphatidylcholine metabolic process	1	4213.0×	0.001	ABCA3
xenobiotic export from cell	1	2808.7×	0.002	ABCA3
dermatan sulfate proteoglycan catabolic process	1	2106.5×	0.002	IDUA
positive regulation of phospholipid efflux	1	2106.5×	0.002	ABCA3
regulation of lipid biosynthetic process	1	1404.3×	0.002	ABCA3
organelle assembly	1	1404.3×	0.002	ABCA3
glycosaminoglycan catabolic process	1	1203.7×	0.002	IDUA
positive regulation of phospholipid transport	1	1203.7×	0.002	ABCA3
heparan sulfate proteoglycan catabolic process	1	936.2×	0.002	IDUA
phosphatidylglycerol metabolic process	1	702.2×	0.003	ABCA3
phospholipid homeostasis	1	495.6×	0.003	ABCA3
xenobiotic transmembrane transport	1	468.1×	0.003	ABCA3
xenobiotic transport	1	421.3×	0.003	ABCA3
surfactant homeostasis	1	401.2×	0.003	ABCA3
phosphatidylcholine metabolic process	1	401.2×	0.003	ABCA3
phospholipid transport	1	351.1×	0.004	ABCA3
positive regulation of cholesterol efflux	1	312.1×	0.004	ABCA3
response to glucocorticoid	1	162.0×	0.007	ABCA3
lipid transport	1	131.7×	0.008	ABCA3
lung development	1	99.1×	0.011	ABCA3
response to xenobiotic stimulus	1	34.5×	0.029	ABCA3

Therapeutics

Drugs indicated for this disease

7 approved, 19 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Approved (phase 4)
Albumin Human	Approved (phase 4)
Beractant	Approved (phase 4)
Calfactant	Approved (phase 4)
Itraconazole	Approved (phase 4)
Pirfenidone	Approved (phase 4)
Poractant Alfa	Approved (phase 4)
Albuterol	Phase 3 (in late-stage trials)
Amphotericin B	Phase 3 (in late-stage trials)
Azithromycin	Phase 3 (in late-stage trials)
Ceftolozane	Phase 3 (in late-stage trials)
Colchicine	Phase 3 (in late-stage trials)
Dexmedetomidine	Phase 3 (in late-stage trials)
Fentanyl	Phase 3 (in late-stage trials)
Furosemide	Phase 3 (in late-stage trials)
Gabapentin	Phase 3 (in late-stage trials)
Ketamine	Phase 3 (in late-stage trials)
Meropenem	Phase 3 (in late-stage trials)
Midazolam	Phase 3 (in late-stage trials)
Nitric Oxide	Phase 3 (in late-stage trials)
Rituximab	Phase 3 (in late-stage trials)
Sildenafil	Phase 3 (in late-stage trials)
Sodium Chloride	Phase 3 (in late-stage trials)
Tazobactam	Phase 3 (in late-stage trials)
Thrombin	Phase 3 (in late-stage trials)
Triamcinolone	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amikacin, Azathioprine, Bedaquiline, Catequentinib, Cefoxitin, Clarithromycin, Clofazimine, Co-Trimoxazole, Cyclosporine, Dapsone, Ethambutol, INTERFERON GAMMA-1B, Indacaterol, Linezolid, Moxifloxacin, Prednisone, Rifabutin, Salmeterol, Tacrolimus Anhydrous, Tigecycline, Tocilizumab.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ABCA3	0	0
IDUA	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
IDUA	15	Binding:15

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
IDUA	3.2.1.76	L-iduronidase

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	2	ABCA3, IDUA
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
ABCA3	0	—
IDUA	15	—

Clinical trials & evidence

Clinical trials

Clinical trials: 865.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	670
PHASE3	65
PHASE2	47
PHASE1	34
PHASE4	25
PHASE1/PHASE2	12
PHASE2/PHASE3	9
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04263038	PHASE4	RECRUITING	Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT05967117	PHASE4	RECRUITING	Chest CT Using Low-concentration Iodine Contrast Media
NCT00075179	PHASE4	TERMINATED	Natrecor in Pulmonary Hypertension
NCT00139152	PHASE4	COMPLETED	Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
NCT00146497	PHASE4	TERMINATED	Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants
NCT00233064	PHASE4	COMPLETED	Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)
NCT00367913	PHASE4	COMPLETED	Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
NCT00704171	PHASE4	COMPLETED	PleuraSeal Post Market Study (Europe)
NCT01148706	PHASE4	COMPLETED	Effectiveness of ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Procedures
NCT01183182	PHASE4	COMPLETED	Safety and Effectiveness Study for a Needle Guidance System in Lung Biopsies
NCT01236495	PHASE4	COMPLETED	Comparison for Pethidine Requirement in Patients Received Spinal Morphine 0.2 and 0.3 mg for Post Lobectomy Analgesia
NCT01326611	PHASE4	COMPLETED	Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants
NCT01377051	PHASE4	COMPLETED	Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea
NCT01443845	PHASE4	COMPLETED	Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
NCT01460108	PHASE4	UNKNOWN	AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation
NCT02282384	PHASE4	WITHDRAWN	An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.
NCT02330952	PHASE4	COMPLETED	Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD
NCT02596048	PHASE4	COMPLETED	A Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA)
NCT02668978	PHASE4	COMPLETED	SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial Using HEMOPATCH
NCT03905837	PHASE4	COMPLETED	Impact of Lidocaine Administration on Postoperative Complications During Lung Resection Surgery
NCT03937583	PHASE4	UNKNOWN	Screening for Cancer in Patients With Unprovoked VTE
NCT04319705	PHASE4	UNKNOWN	Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
NCT05077111	PHASE4	UNKNOWN	A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia
NCT05144828	PHASE4	COMPLETED	Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection
NCT06272370	PHASE4	COMPLETED	Individualizing Treatment for Asthma in Primary Care
NCT03683186	PHASE3	ENROLLING_BY_INVITATION	A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT05596786	PHASE3	RECRUITING	Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial
NCT06431633	PHASE3	RECRUITING	Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
NCT00000548	PHASE3	COMPLETED	Inhaled NO in Prevention of Chronic Lung Disease
NCT00000562	PHASE3	COMPLETED	Extracorporeal Support for Respiratory Insufficiency (ECMO)
NCT00000563	PHASE3	COMPLETED	Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration
NCT00000564	PHASE3	COMPLETED	Nocturnal Oxygen Therapy
NCT00000565	PHASE3	COMPLETED	Clinical Study of Intermittent Positive Pressure Breathing (IPPB)
NCT00000566	PHASE3	COMPLETED	Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED)
NCT00000567	PHASE3	COMPLETED	High Frequency Ventilation in Premature Infants (HIFI)
NCT00000568	PHASE3	COMPLETED	Lung Health Study (LHS) I and III
NCT00000569	PHASE3	COMPLETED	Lung Health Study II
NCT00000570	PHASE3	COMPLETED	Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial
NCT00000571	PHASE3	COMPLETED	Trial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease
NCT00000572	PHASE3	COMPLETED	Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXMEDETOMIDINE	4	4
PEMETREXED	4	3
THEOPHYLLINE ANHYDROUS	4	3
ALBUTEROL	4	2
AZATHIOPRINE	4	2
BECLOMETHASONE DIPROPIONATE	4	2
INDACATEROL	4	2
IPRATROPIUM	4	2
NEDOCROMIL	4	2
NITRIC OXIDE	4	2
PRALSETINIB	4	2
ALFENTANIL	4	1
AMIKACIN SULFATE	4	1
AMPHOTERICIN B	4	1
AZITHROMYCIN	4	1
BELUMOSUDIL	4	1
BUDESONIDE	4	1
CEFTOLOZANE	4	1
CLARITHROMYCIN	4	1
COLCHICINE	4	1
DAPSONE	4	1
DEXTROSE	4	1
DOBUTAMINE	4	1
ETHAMBUTOL	4	1
FLUDEOXYGLUCOSE	4	1
FUROSEMIDE	4	1
HYDROXYCHLOROQUINE SULFATE	4	1
INTERFERON GAMMA-1B	4	1
IOHEXOL	4	1
IOPAMIDOL	4	1